Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 2, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 6, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001713795-26-000002
Filed / recorded
Jan 6, 2026, 9:21 PM UTC
Added to OQRO
Oct 7, 2026, 5:51 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
LENZ Therapeutics, Inc.
Issuer CIK
1815776
Ticker
LENZ
Reporting person
Evert B. Schimmelpennink
Relationship
Director, Officer
Officer title
President, CEO and Secretary
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Jan 2, 2026
Transaction code
A
Shares / units
358,100
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
358,100
Ownership form
Direct
Amendment
No
Footnotes from the filing
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026.